Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together leaders in the field of translational mitochondrial medicine, with a programme designed to engage and inspire the next generation of mitochondrial researchers. Read more about the event.
Find more articles
- Disease spotlight: Cognition and mitochondrial disease
- Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease
- MELAS Syndrome
- Khondrion appoints Rob van Maanen as Chief Medical Officer
- Interview with Julien Beyrath, Chief Scientific Officer at Khondrion
- Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases
- Khondrion becomes partner in DuSRA-VOILA collaboration
- CEO Jan Smeitink on Khondrion’s development program and plans for 2020
- Reflections on the Mitochondrial Medicine 2019 Conference
- Khondrion strengthens executive team with COO Arnout Ploos van Amstel
- Mitochondrial Medicine 2019
- Khondrion is collaborating globally on its way to market
- Reflections on SSIEM annual symposium 2019 – Building Bridges
- Khondrion granted Orphan Drug Designation for KH176 for the treatment of MIDD from European Commission
- BIO-Europe 2018: Interview with Mike Ward, Chief Content Officer at Informa Pharma Insights
- New Year brings new look at khondrion.com
- Scientific publication in Cell Death & Disease
- Jan Smeitink interview with Catalyze
- Publication of the KHENERGY study results
- Khondrion awarded H2020 SME Instrument grant
- KH176 published in Scientific Reports
- Khondrion presents Phase II KHENERGY trial data
- Khondrion will present first results of KHENERGY study
- New Patents granted for KH176
- KHENERGY: completion of recruitment and first-in-patient dosing